Clinicians should be alert for invasive serogroup Y meningococcal disease in at-risk populations and those with unusual symptoms amid the highest annual number of cases reported since 2014, according ...

Effective vaccines provide direct protection to immunized individuals, but may also provide benefits to unvaccinated individuals by reducing transmission and thereby lowering the risk of infection.

Complete vaccination with the four-component, protein-based meningococcal serogroup B vaccine (4CMenB; Bexsero) was found to be effective in the prevention of invasive serogroup B and non-serogroup B ...

Please provide your email address to receive an email when new articles are posted on . The CDC’s Advisory Committee on Immunization Practices is developing new guidelines for state and local health ...

The U.S. Food and Drug Administration announced today the approval of Trumenba, the first vaccine licensed in the United States to prevent invasive meningococcal disease caused by Neisseria ...

The U.S. Food and Drug Administration today approved Bexsero, a vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age ...

Please provide your email address to receive an email when new articles are posted on . The FDA today approved the recombinant vaccine, Bexsero, for prevention of Neisseria meningitidis serogroup B ...

(HealthDay News) — College students have an increased risk for sporadic and outbreak-associated serogroup B meningococcal disease, according to a study published online Dec. 31 in Pediatrics. Sarah A.

From 1995, the UK experienced an increase in morbidity and mortality due to serogroup C meningococcal disease, predominantly owing to the introduction and spread of a hyperinvasive clone associated ...